Development of oral agent in the treatment of multiple sclerosis: How the first available oral therapy, fngolimod will change therapeutic paradigm approach

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 175-186

  Gasperini, Claudio ^a   Ruggieri, Serena ^b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Fingolimod; Fty720; Multiple sclerosis; Oral compounds; Patient satisfaction; Phosphate; Sphingosine 1

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; LAQUINIMOD; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ABNORMAL LABORATORY RESULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC ENCEPHALOMYELITIS; ALOPECIA; AMYLASE BLOOD LEVEL; ANKLE EDEMA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ATRIOVENTRICULAR BLOCK; AUTOIMMUNE DISEASE; BACKACHE; BASAL CELL CARCINOMA; BLEEDING; BOWEN DISEASE; BRADYCARDIA; BRAIN DISEASE; BRAIN HEMORRHAGE; BREAST CANCER; BUDD CHIARI SYNDROME; CONTRAST ENHANCEMENT; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENCEPHALITIS; EXPERIMENTAL AUTOIMMUNE NEURITIS; FAINTNESS; FATIGUE; FIBRINOGEN BLOOD LEVEL; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEMOGLOBIN BLOOD LEVEL; HERPES SIMPLEX; HERPES ZOSTER; HOT FLUSH; HUMAN; HYPERTENSION; HYPOPHYSIS ADENOMA; IMMUNOMODULATION; INFECTION; KIDNEY GRAFT REJECTION; LATENT TUBERCULOSIS; LEUKEMIA; LEUKOCYTE COUNT; LIMB PAIN; LIVER TOXICITY; LONG TERM CARE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEAN ARTERIAL PRESSURE; MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NAUSEA; NECROTIC FOCAL ENCEPHALITIS; NEOPLASM; NEURITIS; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURISY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RESPIRATORY TRACT INFECTION; RETINA MACULA EDEMA; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; SKIN CANCER; SORE THROAT; TREATMENT DURATION; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; ANIMAL; COMPARATIVE STUDY; DRUG DESIGN; DRUG EFFECT; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; DRUG DESIGN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84867916552     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S8927     Document Type: Review

References (49)

1. Weinshenker BG, Bass B, Rice G P, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133-146.
2. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ. 2006; 332:525-527.
3. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-1517.
4. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129:606-616.
5. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17:210-218.
6. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med. 2006;354:942-955.
7. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profles. CNS Drugs. 2005;19:239-252.
8. US Food and Drug Administration. FDA approves frst oral drug to reduce MS relapses [press release]. Silver Spring, MD: US Food and Drug Administration. September 22, 2010. Available at: http://www. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755. htm. Accessed February 27, 2012.
9. Therapeutic Goods Administration, Department of Health and Ageing (Australia). Australian Public Assessment Report for Cladribine Tablets. July 2011. Available at: http://www.tga.gov.au/pdf/auspar/auspar-movectro.pdf. Accessed February 27, 2012.
10. Giovannoni G, Comi G, Cook S, et al; CLARITY Study Group. A placebo controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-426.
11. Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. 2011;17(5):578-593.
12. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol. 1998;139,390-395.
13. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol. 2006;13(6):604-610.
14. Kappos L, Gold R, Miller DH, et al; BG-12 Phase IIb Study Investigators. Effcacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463-1472.
15. Bruneau JM, Ye a CM, Spinella-Jeagle S, et al. Purifcation of human dihydroorotate dehydrogenase and its inhibition by A77 1726, the active metabolite of lefunomide. Biochem. 1998;J336:299-303.
16. Korn T, Toyka K, Hartung H P, Jung S. Suppression of experimental autoimmune neuritis by lefunomide. Brain. 2001;124:1791-1802.
17. Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - mechanisms independent of pyrimidine depletion. J Leukoc Biol. 2004;76:950-960.
18. O'Connor P W, Li D, Freedmann MS, et al. A phase II study of the safety and effcacy of terifunomide in multiple sclerosis with relapses. Neurolog y. 2006;66:894-900.
19. O'Connor P W, Wolinsky JS, Confavreux C, et al. A placebo-controlled phase III trial (TEMSO) of oral terifunomide in relapsing multiple sclerosis: clinical effcacy and safety outcomes. Abstract presented at: ECTRIMS 2010. Proceedings of the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 15, 2010; Gothenburg, Sweden.
20. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGFβ in Lewis rats. J Neuroimmunol. 2004;156:3-9.
21. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371:2085-2092.
22. Comi G, Jeffrey D, Kappos L, et al. Oral laquinimod reduced relapse rate and delayed progression of disability in ALLEGRO, a placebo-controlled phase III trial for relapsing-remitting multiple sclerosis. Abstract presented at: AAN 2011. American Academy of Neurology 63rd Annual Meeting; April 15, 2011; Honolulu, HI. Abst #P05.288.
23. Vollmer TL, Soelberg Sorensen P. Arnold DL on behalf of the BRAVO study. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis [abstract]. Mult Scler. 2011;17:S507-524.
24. Brinkmann V. FTY720 (fngolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158:1173-1182.
25. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 2007;323:469-475.
26. Salvadori M, Budde K, Charpentier B, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant. 2006;6:2912-2921.
27. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo). 1994;47:208-215.
28. Chun J, Hartung H P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2): 91-110.
29. Takabe K, Paugh S W, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60:181-195.
30. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem. 2004;92(5):913-922.
31. Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther. 2008;117:77-93.
32. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84-105.
33. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol. 2007;8(12):1295-1301.
34. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem. 2004;73:321-354.
35. Oo ML, Thangada S, Wu MT, et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007;282:9082-9089.
36. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol. 2004;44:532-537.
37. Budde K, L Schmouder R, Nashan B, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002;13:1073-1083.
38. Kataoka H, Sugahara K, Shimano K, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infltration. Cell Mol Immunol. 2005;2(6):439-448.
39. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther. 2003;305(1):70-77.
40. Kappos L, Antel J, Comi G, et al. Oral fngolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124-1140.
41. O'Connor P, Comi G, Montalban X, et al. Oral fngolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009;72(1):73-79.
42. Comi G, O'Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16(2):197-207.
43. Cohen JA, Barkhof F, Comi G, et al. Oral fngolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
44. Kappos L, Radue E W, O'Connor P, et al. A placebo-controlled trial of oral fngolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):387-401.
45. Kovarik JM, Slade A, Riviere GJ, et al. The ability of atropine to prevent and reverse the negative chronotropic effect of fngolimod in healthy subjects. Br J Clin Pharmacol. 2008;66(2):199-206.
46. Leypoldt F, Münchau A, Moeller F, Bester M, Gerloff C, Heesen C. Hemorrhaging focal encephalitis under fngolimod (FTY720) treatment: a case report. Neurology. 2009;72(11):1022-1024.
47. European Medicines Agency EPAR summary: available from: http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002202/WC500104530.pdf. Accessed February 27, 2012.
48. European Medicines Agency. Questions and answers on the ongoing review of Gilenya (fngolimod). January 19, 2012. Available from http:// www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/human/002202/WC500120704.pdf. Accessed February 27, 2012.
49. Kasper LH, Due BR; ONO-4641 Study Group. A phase I study to evaluate safety, tolerability and pharmacological properties of a selective sphingosine-1-phosphate (S1P) receptor agonist ONO-4641 in patients with multiple sclerosis [poster no. P991]. Presented at ECTRIMS 2010. Proceedings of the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; October 15, 2010; Gothenburg, Sweden.